After a global consensus process involving over 14,000 survey responses and input from 56 organizations worldwide, the condition formerly known as polycystic ovarian syndrome (PCOS) has been officially renamed. The new name is PMOS1, which stands for polyendocrine metabolic ovarian syndrome. The change reflects a shift in how the medical community understands a condition that affects an estimated 170 million women globally.
The old name, polycystic ovary syndrome, was always somewhat misleading. The condition does not actually involve pathological ovarian cysts, despite what the name suggested. What appear as cysts on some ultrasounds are actually immature follicles, which are a symptom of hormonal dysfunction rather than its cause. This naming confusion had real consequences for diagnosis and treatment.
By centering the ovaries, the old terminology obscured the condition’s true nature as a multi-system syndrome involving hormones, metabolism, and ovarian function. Research confirms the scope of the problem. A 2025 study found that while population-based data show PCOS prevalence of 4 to 19.6 percent, health system records capture only 0.2 to 5.2 percent. This diagnostic gap is not evenly distributed. Studies show that Black and African American patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.
The new name breaks down into three components. Polyendocrine means the condition involves multiple hormone systems, including reproductive hormones, androgens like testosterone, insulin, and neuroendocrine hormones that affect everything from mood to metabolism. Metabolic means insulin resistance is a core feature for many women with this condition, carrying significant downstream risks. Ovarian means ovarian dysfunction remains part of the picture, capturing irregular cycles, anovulation, and fertility challenges, now understood as one piece of a larger puzzle.
The metabolic component deserves particular attention. A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms like hyperandrogenism and ovulatory dysfunction. PMOS itself also increases the risk of type 2 diabetes. This is further evidence of how PMOS has reproductive, metabolic, and psychological impacts across a person’s lifespan.
Clearer terminology could improve diagnosis. When clinicians heard PCOS, they thought polycystic ovaries and looked for ovarian cysts and menstrual irregularities. When they hear polyendocrine metabolic ovarian syndrome, the diagnostic lens widens considerably. This matters because many women with PMOS do not fit the narrow classic presentation. Some have regular periods. Others present with irregular menstrual cycles but do not have visible follicles on an ultrasound. Symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers point to the same underlying dysfunction.
The hope is that reframing the condition as metabolic and endocrine, rather than simply gynecological, will prompt earlier and more comprehensive screening. A woman presenting with unexplained weight gain, fatigue, and skin changes might now be evaluated for PMOS rather than having her symptoms dismissed or siloed into separate specialty visits. This name change validates what many patients have long known. The condition is not just about the ovaries. It is a whole-body condition that deserves whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health.
